Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KDM1A | O60341 | 3/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | MGLL | Q99685 | 2/20 | 0.60 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9080564 | 0.90 | POLB (0.68) | POLBTP53MAPTKDM1AMAOA | |
| Benzyl Phenylcarbamate SCHEMBL1222943 | 0.88 | POLB (0.78) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL97680 | 0.87 | NPC1 (0.57) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL1870929 | 0.87 | POLB (0.71) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL10598558 | 0.85 | POLB (0.69) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL10595799 | 0.84 | POLB (0.73) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL3795024 | 0.84 | POLB (0.68) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL7663567 | 0.84 | POLB (0.68) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL5700992 | 0.84 | POLB (0.68) | POLBTP53MAPTKDM1AMAOA | |
| SCHEMBL3694153 | 0.84 | POLB (0.68) | POLBTP53MAPTKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | claimed |
| CN-101094833-A | Tetrapeptide analogs | IDUN PHARMACEUTICALS INC (US) | 2007-12-26 | — | — | CN | claimed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | claimed |
| US-6624152-B2 | Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-09-23 | — | — | US | claimed |
| US-20030083267-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2003-05-01 | — | — | US | claimed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | claimed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | claimed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | claimed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | claimed |
| US-6172064-B1 | METALLOPROTEASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIDIABETIC AGENTS; ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-01-09 | — | — | US | claimed |
| WO-2000012082-A1 | FORMAMIDE COMPOUNDS AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | claimed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | claimed |
| EP-0145304-B1 | TETRAHYDRO-BETA-CARBOLINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Tanabe Seiyaku Co., Ltd. (JP) | 1988-04-20 | — | — | EP | claimed |
| US-4663319-A | LIVER DISORDERS | TANABE SEIYSKU CO., LTD. (JP) | 1987-05-05 | — | — | US | claimed |
| US-4628057-A | Tetrahydro-β-carboline derivatives and treatment of liver diseases | TANABE SEIYAKU CO., LTD. (JP) | 1986-12-09 | — | — | US | claimed |
| EP-0145304-A1 | Tetrahydro-beta-carboline derivatives and process for the preparation thereof | Tanabe Seiyaku Co., Ltd. (JP) | 1985-06-19 | — | — | EP | claimed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2457896-A1 | Tripeptides as caspase modulators | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2457895-A1 | Tetrapeptide analogs | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-1942472-B | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORP. (KR) | 2012-02-15 | — | — | CN | disclosed |
| CN-101068810-B | Carbostyril compound | OTSUKA PHARMA CO LTD | 2011-02-09 | — | — | CN | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| CN-1798746-B | Reverse turn mimetics and methods relating thereto | CHOONGWAE PHARMA CORP | 2010-09-08 | — | — | CN | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| CN-100475816-C | Reverse turn mimetics and methods relating thereto | CHOONGWAE PHARMA CORP (KR) | 2009-04-08 | — | — | CN | disclosed |
| EP-1444235-B1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORP (KR) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| CN-101094833-A | Tetrapeptide analogs | IDUN PHARMACEUTICALS INC (US) | 2007-12-26 | — | — | CN | disclosed |
| CN-101068810-A | Carbostyril compound | OTSUKA PHARMA CO LTD (JP) | 2007-11-07 | — | — | CN | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| CN-1942472-A | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORP (KR) | 2007-04-04 | — | — | CN | disclosed |
| CN-1872857-A | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORP (KR) | 2006-12-06 | — | — | CN | disclosed |
| CN-1872856-A | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORP (KR) | 2006-12-06 | — | — | CN | disclosed |
| US-20060166866-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| CN-1798746-A | Reverse turn mimetics and methods relating thereto | CHOONGWAE PHARMA CORP (KR) | 2006-07-05 | — | — | CN | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| US-7001921-B1 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2006-02-21 | — | — | US | disclosed |
| CN-1585770-A | Reverse turn mimetics and methods relating thereto | CHOONGWAE PHARMA CORP (KR) | 2005-02-23 | — | — | CN | disclosed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | disclosed |
| US-6624152-B2 | Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030083267-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2003-05-01 | — | — | US | disclosed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| US-6329400-B1 | INHIBITION OR ANTAGONISM OF MATRIX METALLOPROTEASES, AND/OR TUMOR NECROSIS FACTOR-ALPHA; EXTRACELLULAR MATRIX DEGRADATION, INHIBITION OF SHEDDING OF CELL SURFACE PROTEIN ECTODOMAINS AND CD23 PROTEOLYSIS | GLAXO WELLCOME INC. | 2001-12-11 | — | — | US | disclosed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6274715-B1 | SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | disclosed |
| US-6172064-B1 | METALLOPROTEASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIDIABETIC AGENTS; ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-01-09 | — | — | US | disclosed |
| CN-1268117-A | Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis | DU PONT PHARM CO (US) | 2000-09-27 | — | — | CN | disclosed |
| CN-1244202-A | Tricyclic erythromycin derivatives | ABBOTT LAB (US) | 2000-02-09 | — | — | CN | disclosed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
| EP-0145304-B1 | TETRAHYDRO-BETA-CARBOLINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Tanabe Seiyaku Co., Ltd. (JP) | 1988-04-20 | — | — | EP | disclosed |
| US-4663319-A | LIVER DISORDERS | TANABE SEIYSKU CO., LTD. (JP) | 1987-05-05 | — | — | US | disclosed |
| US-4628057-A | Tetrahydro-β-carboline derivatives and treatment of liver diseases | TANABE SEIYAKU CO., LTD. (JP) | 1986-12-09 | — | — | US | disclosed |
| EP-0149534-A2 | Novel thioketene derivatives and process for the preparation thereof | Tanabe Seiyaku Co., Ltd. (JP) | 1985-07-24 | — | — | EP | disclosed |
| EP-0145304-A1 | Tetrahydro-beta-carboline derivatives and process for the preparation thereof | Tanabe Seiyaku Co., Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
| EP-0145304-A1 | Tetrahydro-beta-carboline derivatives and process for the preparation thereof | Tanabe Seiyaku Co., Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166866-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | POLB 4750/4885TP53 3223/4885MAPT 2771/4885 |
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | POLB 1340/4885TP53 3154/4885MAPT 4112/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | POLB 4329/4885TP53 1280/4885MAPT 4773/4885 |
| US-20030083267-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | POLB 4750/4885TP53 3223/4885MAPT 2771/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | POLB 4329/4885TP53 1280/4885MAPT 4773/4885 |
| US-20100190688-A1 | Tetrapeptide analogs | TP53, PCNA, HRAS | POLB 97/4885TP53 1/4885MAPT 3476/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | POLB 4750/4885TP53 3223/4885MAPT 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.